We are live on
!
Find out more
ABG
Ally Bridge Group Portfolio holdings
AUM
$124M
1-Year Est. Return
249.88%
This Fund
S&P 500
This Quarter
Est. Return
-10.15%
1 Year Est. Return
+249.88%
3 Year Est. Return
+942.29%
5 Year Est. Return
+671.08%
10 Year Est. Return
–
AUM
$286M
AUM Growth
-$54M
(-16%)
Cap. Flow
-$16.7M
Cap. Flow
% of AUM
-5.83%
Top 10 Holdings %
Top 10 Hldgs %
53.89%
Holding
37
New
6
Increased
5
Reduced
8
Closed
7
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ISO
IsoPlexis Corporation Common Stock
ISO
|
+$19.6M |
| 2 |
Guardant Health
GH
|
+$10.9M |
| 3 |
Sarepta Therapeutics
SRPT
|
+$10.3M |
| 4 |
Lantheus
LNTH
|
+$8.78M |
| 5 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
+$4.92M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gossamer Bio
GOSS
|
+$8.31M |
| 2 |
MacroGenics
MGNX
|
+$6.31M |
| 3 |
NVTA
Invitae Corporation
NVTA
|
+$5.68M |
| 4 |
Viridian Therapeutics
VRDN
|
+$5.59M |
| 5 |
AMRS
Amyris Inc.
AMRS
|
+$4.84M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 97.94% |
| 2 | Financials | 2.06% |
| 3 | Materials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Stoke Therapeutics
STOK
$1.82B
| $4.44M | 1.55% |
+185,000
| New | +$4.41M |
|
|
MDVL
27
DELISTED
MedAvail Holdings, Inc. Common Stock
MDVL
| $4.09M | 1.43% |
58,416
| – | – |
|
|
VERV
28
DELISTED
Verve Therapeutics
VERV
| $4.07M | 1.42% |
110,360
+95,360
| +636% | +$4.01M |
|
|
CYT
29
DELISTED
Cyteir Therapeutics, Inc. Common Stock
CYT
| $3.63M | 1.27% |
319,538
| – | – |
|
|
30
MacroGenics
MGNX
$235M
| $482K | 0.17% |
30,000
-335,000
| -92% | -$6.31M |
|
31
Adicet Bio
ACET
$72.8M
| – | – |
-26,563
| Closed | -$3.33M |
|
|
APLS
32
CALL
DELISTED
Apellis Pharmaceuticals
APLS
| – | – |
-300,000
| Closed | -$9.89M |
|
33
Bolt Biotherapeutics
BOLT
$7.36M
| – | – |
-12,863
| Closed | -$3.25M |
|
34
PUT
State Street SPDR NYSE Technology ETF
XNTK
$2.06B
| – | – |
-200,000
| Closed | -$25.1M |
|
|
NVTA
35
DELISTED
Invitae Corporation
NVTA
| – | – |
-199,900
| Closed | -$5.68M |
|
|
CELL
36
DELISTED
PhenomeX Inc. Common Stock
CELL
| – | – |
-201,996
| Closed | -$3.95M |
|
|
AMRS
37
DELISTED
Amyris Inc.
AMRS
| – | – |
-352,445
| Closed | -$4.84M |
|
Similar funds
MP
EWP
WFA
VWM
EI
TC
IFO
CRW
Ally Bridge Group's Q4 2021 Portfolio in Review
As of Q4 2021, Ally Bridge Group held 37 positions worth $286M, down 16% from $340M the previous quarter. Its ten largest holdings account for 54% of the portfolio.
Ally Bridge Group withdrew a net $16.7M in Q4 2021, closing 7 positions and reducing 8 holdings. Its most notable exit was Invitae Corporation, an estimated $5.68M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 85% a quarter earlier, followed by Financials and Materials.
Against the trend, Ally Bridge Group opened a new position in IsoPlexis Corporation Common Stock worth $16.3M.
- Ally Bridge Group's largest Q4 2021 buy was IsoPlexis Corporation Common Stock: 1,770,118 shares worth $16.3M.
- Ally Bridge Group added most to IVERIC bio, Inc. Common Stock in Q4 2021, an estimated $4.92M increase.
- Ally Bridge Group's biggest Q4 2021 reduction was Gossamer Bio, cutting an estimated $8.31M.
- Ally Bridge Group fully exited Invitae Corporation in Q4 2021, selling an estimated $5.68M.
- Ally Bridge Group's ten largest holdings make up 54% of its $286M portfolio in Q4 2021.
- Ally Bridge Group opened 6 new positions and closed 7 in Q4 2021.
- Ally Bridge Group's portfolio value fell 16% quarter-over-quarter to $286M.
Based on Ally Bridge Group's 13F filing for Q4 2021, filed 14 Feb 2022.